Tourmaline Bio 13G Filing Shows Pfizer Inc Reported A 6.26% Stake In Co As Of October 19, 2023
Portfolio Pulse from Benzinga Newsdesk
Pfizer Inc has reported a 6.26% stake in Tourmaline Bio as of October 19, 2023, according to a 13G filing with the SEC.
October 27, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer Inc has increased its portfolio by acquiring a 6.26% stake in Tourmaline Bio.
Pfizer's acquisition of a stake in Tourmaline Bio is a strategic investment, which could potentially bring new opportunities for the company. However, as the stake is relatively small, it's unlikely to have a significant impact on Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Tourmaline Bio has attracted investment from Pfizer Inc, which now holds a 6.26% stake in the company.
The investment from a major pharmaceutical company like Pfizer Inc could boost confidence in Tourmaline Bio and potentially drive its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100